iRhythm HoldingsIRTC +1.53%75 3-Year RORE % is -40.95 as of Mar. 2026. GuruFocus rates IRTC with a GF Score™ of 75/100 and a GF Value™ of $163.30 (Modestly Undervalued). Among 782 Medical Devices & Instruments companies, iRhythm Holdings ranks worse than 78.39% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
iRhythm Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was -40.95%.
The industry rank for iRhythm Holdings's 3-Year RORE % or its related term are showing as below:
IRTC's 3-Year RORE % is ranked worse than 78.39% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.31
vs IRTC: -40.95
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
iRhythm Holdings 3-Year RORE % Related Terms
iRhythm Holdings 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for iRhythm Holdings's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, iRhythm Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
iRhythm Holdings (IRTC) has a 3-Year RORE % of -40.95 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on iRhythm Holdings and its competitors. According to the industry distribution chart, iRhythm Holdings ranks #613 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 78.4%.
Is iRhythm Holdings' 3-Year RORE % too high?
iRhythm Holdings' current 3-Year RORE % is -40.95. Based on the distribution chart, iRhythm Holdings ranks #613 out of 782 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iRhythm Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' 3-Year RORE % compare to HAE and LIVN?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #613 out of 782 companies for 3-Year RORE %. This places iRhythm Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on iRhythm Holdings and its competitors. iRhythm Holdings's current 3-Year RORE % is -40.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Modestly Undervalued. The stock's GF Value™ is $163.30, compared to a current price of $126.48 — trading 22.5% below its estimated fair value. The current 3-Year RORE % is -40.95. iRhythm Holdings' overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current 3-Year RORE % is -40.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $126.48 is trading 22.5% below its estimated GF Value™ of $163.30.
GuruFocus considers iRhythm Holdings to be Modestly Undervalued.
Key valuation signals for IRTC:
3-Year RORE %: -40.95
GF Value™: $163.30 vs. price of $126.48 (22.5% below fair value)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
75GF Score
Get the complete analysis for IRTC
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
